Autolus Therapeutics (AUTL) Total Current Liabilities (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Total Current Liabilities for 9 consecutive years, with $73.4 million the latest figure, recorded in Q4 2025.

• Quarterly Total Current Liabilities rose 20.9% year-over-year to $73.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $73.4 million (up 20.9% YoY) and the FY2025 annual result came in at $73.4 million, up 20.9% from the prior year.
• Total Current Liabilities slipped to $73.4 million in Q4 2025 per AUTL's latest filing, from $83.1 million in the prior quarter.
• Over the last five years, Total Current Liabilities for AUTL reached as high as $83.1 million in Q3 2025 and fell as low as $28.2 million in Q2 2021.
• A 5-year average of $46.2 million and a median of $41.0 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Current Liabilities fell 15.11% — and 2025, when it jumped 66.61%.
• Year by year, Total Current Liabilities stood at $28.6 million in 2021, then surged by 62.4% to $46.4 million in 2022, then declined by 3.51% to $44.7 million in 2023, then surged by 35.78% to $60.7 million in 2024, then climbed by 20.9% to $73.4 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $73.4 million, $83.1 million, and $68.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.